Eli Lilly and Company $LLY Shares Purchased by Chicago Partners Investment Group LLC

Chicago Partners Investment Group LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 21,974 shares of the company’s stock after purchasing an additional 570 shares during the quarter. Chicago Partners Investment Group LLC’s holdings in Eli Lilly and Company were worth $20,249,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Gratus Wealth Advisors LLC raised its position in shares of Eli Lilly and Company by 0.8% in the first quarter. Gratus Wealth Advisors LLC now owns 1,814 shares of the company’s stock valued at $1,668,000 after buying an additional 14 shares during the last quarter. Parr Mcknight Wealth Management Group LLC boosted its position in Eli Lilly and Company by 452.5% during the first quarter. Parr Mcknight Wealth Management Group LLC now owns 6,216 shares of the company’s stock worth $5,717,000 after acquiring an additional 5,091 shares during the last quarter. Uptick Partners LLC boosted its position in Eli Lilly and Company by 8.8% during the first quarter. Uptick Partners LLC now owns 738 shares of the company’s stock worth $679,000 after acquiring an additional 60 shares during the last quarter. AMF Tjanstepension AB grew its stake in Eli Lilly and Company by 2.8% during the 1st quarter. AMF Tjanstepension AB now owns 477,177 shares of the company’s stock valued at $438,893,000 after acquiring an additional 13,138 shares in the last quarter. Finally, Triglav Investments D.O.O. raised its holdings in Eli Lilly and Company by 3.3% in the 1st quarter. Triglav Investments D.O.O. now owns 49,212 shares of the company’s stock valued at $45,265,000 after acquiring an additional 1,566 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Leerink Partners raised their target price on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Morgan Stanley upped their price target on Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the company an “overweight” rating in a research report on Wednesday. Royal Bank Of Canada lifted their price objective on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 8th. Bank of America upped their target price on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a report on Friday. Finally, Berenberg Bank raised their target price on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a research note on Monday, June 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,263.41.

Eli Lilly and Company Trading Up 0.0%

NYSE LLY opened at $1,189.06 on Monday. The firm has a 50 day simple moving average of $1,098.66 and a 200-day simple moving average of $1,033.22. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,249.45. The firm has a market cap of $1.12 trillion, a price-to-earnings ratio of 42.24, a PEG ratio of 1.47 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same period in the prior year, the firm earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 35.81 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Bank of America raised its price target on Eli Lilly to $1,334 from $1,251 and kept a buy rating, signaling confidence that the company still has meaningful upside after its recent run. Benzinga article
• Positive Sentiment: Lilly announced that its Phase 2 neuropathic pain trial reached completion, adding another potentially valuable pipeline asset beyond its blockbuster GLP-1 franchise. TipRanks article
• Positive Sentiment: News flow highlighting record GLP-1 adoption and accelerating sales remains supportive, since Lilly’s obesity and diabetes drugs continue to be the main driver of earnings momentum. Motley Fool article
• Positive Sentiment: Additional analyst commentary has been upbeat, with other firms also lifting targets and framing Lilly as one of the strongest growth names in healthcare. TheStreet article
• Neutral Sentiment: Institutional buying and “best mutual funds” lists suggest Lilly remains a favored large-cap healthcare holding, but this is more a sentiment indicator than a direct catalyst. Yahoo Finance article
• Negative Sentiment: Tampa General’s lawsuit over allegedly pulled 340B discounts adds legal and reimbursement risk, which could create some investor caution around Lilly’s pricing and hospital-channel relationships. Healthcare Finance News article

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.